Phosphatidylserine index as a marker of the procoagulant phenotype of acute myelogenous leukemia cells

Physical Biology

Volumn 10, Issue 5, 2013, Pages

  Tormoen, Garth W ^a   Recht, Olivia ^a   Gruber, András ^a,b   Levine, Ross L ^c   McCarty, Owen J T ^a,b  

^a Oregon Health and Science University Department of Biomedical Engineering   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DAUNORUBICIN; PHOSPHATIDYLSERINE; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD CLOTTING; FLOW CYTOMETRY; HUMAN; METABOLISM; PATHOLOGY; PHENOTYPE; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; BLOOD COAGULATION; CELL LINE, TUMOR; DAUNORUBICIN; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID, ACUTE; PHENOTYPE; PHOSPHATIDYLSERINES; TUMOR MARKERS, BIOLOGICAL;

EID: 84887044680     PISSN: 14783967     EISSN: 14783975     Source Type: Journal    
DOI: 10.1088/1478-3975/10/5/056010     Document Type: Article

References (34)

1. Lopez-Pedrera C, Barbarroja N, Dorado G, Siendones E and Velasco F 2006 Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies Leukemia 20 1331-40
2. Falanga A et al 1995 Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid Blood 86 1072-81
3. Marchetti M, Diani E, ten Cate H and Falanga A 2012 Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography Haematologica 97 1173-80
4. Tanaka M and Yamanishi H 1993 The expression of tissue factor antigen and activity on the surface of leukemic cells Leuk. Res. 17 103-11
5. Tormoen G W, Rugonyi S, Gruber A and McCarty O J 2011 The role of carrier number on the procoagulant activity of tissue factor in blood and plasma Phys. Biol. 8 066005
6. Yan J et al 2010 PML/RARalpha fusion protein transactivates the tissue factor promoter through a GAGC-containing element without direct DNA association Proc. Natl Acad. Sci. USA 107 3716-21
7. Falanga A and Rickles F R 2007 Management of Thrombohemorrhagic Syndromes (THS) in hematologic malignancies Hematol. Am. Soc. Hematol. Educ. Program 2007 165-71
8. Meyer J S and Boxer M 1973 Leukemic cellular thrombi in pulmonary blood vessels. Subleukemic myelogenous leukemia following chloramphenicol-induced aplastic anemia Cancer 32 712-21
9. Takemori N et al 1993 Disseminated intravascular coagulation in a patient with acute myeloid leukemia. Ultrastructural evidence of hypercoagulation in bone marrow Am. J. Clin. Pathol. 99 695-701
10. Engelmann B and Massberg S 2013 Thrombosis as an intravascular effector of innate immunity Nature Rev. Immunol. 13 34-45
11. Shaw A W, Pureza V S, Sligar S G and Morrissey J H 2007 The local phospholipid environment modulates the activation of blood clotting J. Biol. Chem. 282 6556-63
12. Boles J C et al 2012 Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activity Thromb. Res. 129 197-203
13. Wang J, Weiss I, Svoboda K and Kwaan H C 2001 Thrombogenic role of cells undergoing apoptosis Br. J. Haematol. 115 382-91
14. Zhou J et al 2010 Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia J. Thromb. Haemost. 8 773-82
15. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F and Berger R 1991 NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3) Blood 77 1080-6
16. Gallagher R et al 1979 Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia Blood 54 713-33
17. Paul C C, Tolbert M, Mahrer S, Singh A, Grace M J and Baumann M A 1993 Cooperative effects of interleukin-3 (IL-3), IL-5, and granulocyte-macrophage colony-stimulating factor: a new myeloid cell line inducible to eosinophils Blood 81 1193-9
18. White-Adams T C et al 2010 Laminin promotes coagulation and thrombus formation in a factor XII-dependent manner J. Thromb. Haemost. 8 1295-301
19. Berny M A et al 2010 Rational design of an ex vivo model of thrombosis Cell. Mol. Bioeng. 3 187-9
20. Lichtman M A and Rowe J M 1982 Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations Blood 60 279-83
21. Breccia M et al 2007 Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features Leukemia 21 79-83
22. Scharf R E and Schneider W 1990 Relationship of thrombin generation to peripheral blast cell count in patients with acute myeloblastic leukemia (AML) Eur. J. Haematol. 44 273-6
23. Stoffel N, Rysler C, Buser A, Gratwohl A, Tsakiris D A and Stern M 2010 Leukocyte count and risk of thrombosis in patients undergoing haematopoietic stem cell transplantation or intensive chemotherapy Thromb. Haemost. 103 1228-32
24. Brummel-Ziedins K E, Pouliot R L and Mann K G 2004 Thrombin generation: phenotypic quantitation J. Thromb. Haemost. 2 281-8
25. Tormoen G W, Khader A, Gruber A and McCarty O J 2013 Physiological levels of blood coagulation factors IX and X control coagulation kinetics in an in vitro model of circulating tissue factor Phys. Biol. 10 036003
26. Jungi T W 1990 A turbidimetric assay in an ELISA reader for the determination of mononuclear phagocyte procoagulant activity J. Immunol. Methods 133 21-9
27. Langer F et al 2004 An in vitro study on the mechanisms of coagulation activation in acute myelogenous leukemia (AML): role of tissue factor regulation by cytotoxic drugs and GM-CSF Thromb. Haemost. 92 1136-46
28. Oehadian A, Iqbal M and Sumantri R 2009 Deep vein thrombosis in acute myelogenous leukemia Acta. Med. Indones. 41 200-4
29. Falanga A and Marchetti M 2009 Venous thromboembolism in the hematologic malignancies J. Clin. Oncol. 27 4848-57
30. De Stefano V et al 2005 The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment J. Thromb. Haemost. 3 1985-92
31. Ziegler S et al 2005 Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis Thromb. Res. 115 59-64
32. Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G and Franke A 2006 Increased risk of venous thromboembolism in patients with acute leukaemia Br. J. Cancer 94 200-2
33. Ku G H, White R H, Chew H K, Harvey D J, Zhou H and Wun T 2009 Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival Blood 113 3911-7
34. Melillo L, Grandone E, Colaizzo D, Cappucci F, Valvano M R and Cascavilla N 2007 Symptomatic venous thromboembolism and thrombophilic status in adult acute leukemia: a single-center experience of 114 patients at diagnosis Acta. Haematol. 117 215-20